Evidence map›Paper›PMID 26980454›Full record

ArticleNanomedicine (London, England)2016

Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models.

Ana Vanessa Nascimento, Florence Gattacceca, Amit Singh, Hassan Bousbaa, Domingos Ferreira, Bruno Sarmento, Mansoor M Amiji

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer.Journal of functional biomaterials · 2023
    Review
  8. Review
  9. Virus-inspired strategies for cancer therapy.Seminars in cancer biology · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. Mitotic checkpoint defects: en route to cancer and drug resistance.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2021
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Ana Vanessa NascimentoCESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Gandra, Portugal.
Florence GattaccecaInstitut de Recherche en Cancérologie de Montpellier IRCM, INSERM U1194, ICM, Université de Montpellier, Montpellier, France.
Amit SinghDepartment of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA.
Hassan BousbaaCESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Gandra, Portugal.
Domingos FerreiraLaboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Portugal.
Bruno SarmentoCESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Gandra, Portugal.
Mansoor M AmijiDepartment of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA.
Universidade do Porto · PTHealth Sciences North · CAInstitut de Recherche en Cancérologie de Montpellier · FRInstituto de Investigação e Formação Avançada em Ciências e Tecnologias da SaúdeKing Abdulaziz University · SA

Funding

COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCEU01CA151452 · NCI · NORTHEASTERN UNIVERSITY · PI AMIJI, MANSOOR M., DUAN, ZHENFENG · 2010 to 2014
$2.1M
Targeted Platinates/siRNA Combination Therapy for Resistant Lung CancerR21CA179652 · NCI · NORTHEASTERN UNIVERSITY · PI AMIJI, MANSOOR M., IYER, ARUN · 2014 to 2015
$372k
NCI NIH HHS R21 CA179652NCI NIH HHS U01 CA151452
6 · The paper itself

Abstract

backgroundThe present study focuses on biodistribution profile and pharmacokinetic parameters of EGFR-targeted chitosan nanoparticles (TG CS nanoparticles) for siRNA/cisplatin combination therapy of lung cancer. MATERIAL &

methodsMad2 siRNA was encapsulated in EGFR targeted and nontargeted (NTG) CS nanoparticles by electrostatic interaction. The biodistribution of the nanoparticles was assessed qualitatively and quantitatively in cisplatin (DDP) sensitive and resistant lung cancer xenograft model.

resultsTG nanoparticles showed a consistent and preferential tumor targeting ability with rapid clearance from the plasma to infiltrate and sustain within the tumor up to 96 h. They exhibit a sixfold higher tumor targeting efficiency compared with the NTG nanoparticles.

conclusionTG nanoparticles present as an attractive drug delivery platform for RNAi therapeutics against NSCLC.

Indexed as

A549 CellsAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungChitosanCisplatinDrug Delivery SystemsDrug Resistance, NeoplasmErbB ReceptorsFemaleHumansLung NeoplasmsMad2 ProteinsMiceMice, NudeNanoparticlesAntineoplastic AgentsChitosanCisplatinEGFR protein, mouseErbB ReceptorsMad2l1 protein, mouseMad2 ProteinsRNA, Small Interferingbiodistributionchitosan nanoparticlesEGFR targetingMad2 siRNA deliverynon-small-cell lung cancer modelspharmacokinetic analysis

Identifiers

PMID26980454
PMCPMC4910968
OpenAlexW2299270476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.